Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
CC transcript
Appointed director
Quarterly results
|
|
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/02/2023 |
4
| Vakiener Victoria (Director) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 1,550 shares
@ $26.33, valued at
$40.8k
|
|
| 07/06/2023 |
4
| Oliver Tracie (Chief Commercial Officer) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 8,925 shares
@ $35.31, valued at
$315.1k
|
|
| 07/05/2023 |
4
| Hamilton James C (Chief Discovery/Trans Medicine) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 3,000 shares
@ $35.53, valued at
$106.6k
|
|
| 06/29/2023 |
4
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 15,000 shares
@ $36.2, valued at
$543k
|
|
| 05/08/2023 |
4
| GIVEN DOUGLAS B (Director) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 6,500 shares
@ $40.9, valued at
$265.9k
|
|
| 05/05/2023 |
4
| Anzalone Christopher Richard (CEO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 54,928 shares
@ $39.14, valued at
$2.1M
Sold 24,008 shares
@ $38.97, valued at
$935.6k
Sold 25,992 shares
@ $40.02, valued at
$1M
Exercised 54,928 options to buy
@ $2.01, valued at
$110.4k
Exercised 50,000 options to buy
@ $2.01, valued at
$100.5k
|
|
| 03/06/2023 |
4
| OLUKOTUN ADEOYE Y (Director) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 11,350 shares
@ $32.65, valued at
$370.6k
|
|
| 03/01/2023 |
4
| GIVEN DOUGLAS B (Director) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 875 shares
@ $32.62, valued at
$28.5k
|
|
| 01/12/2023 |
4
| Ferrari Mauro (Director) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Granted 7,867 shares
@ $0
Granted 4,593 options to buy
@ $33.03, valued at
$151.7k
|
|
| 01/11/2023 |
4
| De Backer Marianne (Director) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Granted 7,867 shares
@ $0
Granted 4,593 options to buy
@ $33.03, valued at
$151.7k
|
|
| 01/11/2023 |
4
| Vakiener Victoria (Director) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 1,764 shares
@ $0
Granted 7,867 shares
@ $0
Granted 4,593 options to buy
@ $33.03, valued at
$151.7k
|
|
| 01/11/2023 |
4
| PERRY MICHAEL S (Director) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Granted 7,867 shares
@ $0
Granted 4,593 options to buy
@ $33.03, valued at
$151.7k
|
|
| 01/11/2023 |
4
| GIVEN DOUGLAS B (Director) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Granted 7,867 shares
@ $0
Granted 4,593 options to buy
@ $33.03, valued at
$151.7k
|
|
| 01/11/2023 |
4
| Waddill William D. (Director) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 3,200 shares
@ $30, valued at
$96k
Granted 7,867 shares
@ $0
Granted 4,593 options to buy
@ $33.03, valued at
$151.7k
|
|
| 01/11/2023 |
4
| OLUKOTUN ADEOYE Y (Director) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Granted 4,593 options to buy
@ $33.03, valued at
$151.7k
Granted 7,867 shares
@ $0 |
|
| 01/06/2023 |
4
| O'Brien Patrick (COO and General Counsel) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 7,500 shares
@ $37.39, valued at
$280.4k
|
|
| 01/06/2023 |
4
| Hamilton James C (Chief Discovery/Trans Medicine) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 7,230 shares
@ $37.4, valued at
$270.4k
Sold 6,573 shares
@ $37.4, valued at
$245.8k
|
|
| 01/05/2023 |
4
| Oliver Tracie (Chief Commercial Officer) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Granted 500 shares
@ $0 |
|
| 01/05/2023 |
4
| San Martin Javier (Chief Medical Officer) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Granted 60,000 shares
@ $0 |
|
| 01/05/2023 |
4
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Granted 60,000 shares
@ $0 |
|
| 01/05/2023 |
4
| O'Brien Patrick (COO and General Counsel) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 2,653 shares
@ $37.53, valued at
$99.6k
Sold 5,527 shares
@ $38.54, valued at
$213k
Sold 500 shares
@ $39.74, valued at
$19.9k
Sold 70 shares
@ $40.8, valued at
$2.9k
Sold 2,894 shares
@ $37.58, valued at
$108.8k
Sold 5,286 shares
@ $38.58, valued at
$203.9k
Sold 300 shares
@ $39.55, valued at
$11.9k
Sold 270 shares
@ $40.53, valued at
$10.9k
Granted 65,000 shares
@ $0 |
|
| 01/05/2023 |
4
| Hamilton James C (Chief Discovery/Trans Medicine) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 1,194 shares
@ $37.46, valued at
$44.7k
Sold 2,837 shares
@ $38.53, valued at
$109.3k
Sold 300 shares
@ $39.74, valued at
$11.9k
Sold 136 shares
@ $40.54, valued at
$5.5k
Sold 1,642 shares
@ $37.49, valued at
$61.6k
Sold 3,682 shares
@ $38.52, valued at
$141.8k
Sold 300 shares
@ $39.56, valued at
$11.9k
Sold 247 shares
@ $40.52, valued at
$10k
Granted 60,000 shares
@ $0 |
|
| 12/30/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/22/2022 |
4
| O'Brien Patrick (General Counsel) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Exercised 32,000 options to buy
@ $6.15, valued at
$196.8k
|
|
| 12/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/22/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/29/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/12/2022 |
4
| Anzalone Christopher Richard (CEO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 551,197 shares
@ $0 |
|
| 07/11/2022 |
4
| Anzalone Christopher Richard (CEO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Exercised 2,501 options to buy
@ $14.54, valued at
$36.4k
|
|
| 06/29/2022 |
3
| Oliver Tracie (Chief Commercial Officer) has filed a Form 3 on ARROWHEAD PHARMACEUTICALS, INC. |
| 05/05/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 02/14/2022 |
4
| Anzalone Christopher Richard (CEO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 40,853 shares
@ $53.11, valued at
$2.2M
Sold 42,153 shares
@ $52.28, valued at
$2.2M
Sold 61,482 shares
@ $50.9, valued at
$3.1M
Sold 1,900 shares
@ $50.51, valued at
$96k
Exercised 146,388 options to buy
@ $5.19, valued at
$759.8k
|
|
| 01/07/2022 |
4
| Anzalone Christopher Richard (CEO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Exercised 11,806 options to buy
@ $5.19, valued at
$61.3k
|
|
| 01/07/2022 |
4
| O'Brien Patrick (General Counsel) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 12,434 shares
@ $60.49, valued at
$752.1k
Sold 10,350 shares
@ $61.88, valued at
$640.5k
Sold 5,000 shares
@ $62.49, valued at
$312.5k
Sold 4,400 shares
@ $63.75, valued at
$280.5k
Sold 316 shares
@ $64.35, valued at
$20.3k
Gifted 800 shares
@ $0 |
|
|
|
|